BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
891 results:

  • 1. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mtor/AKT pathway.
    Zhou S; Wang Z; Zhao D; Fu Y; Zhang S; Wang Z; Zou X
    World J Surg Oncol; 2024 May; 22(1):133. PubMed ID: 38762741
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Biological activity and computational analysis of novel acrylonitrile derived benzazoles as potent antiproliferative agents for pancreatic adenocarcinoma with antioxidative properties.
    Beč A; Persoons L; Daelemans D; Starčević K; Vianello R; Hranjec M
    Bioorg Chem; 2024 Jun; 147():107326. PubMed ID: 38653153
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Chemically engineered mtor-nanoparticle blockers enhance antitumour efficacy.
    Tang H; Dilimulati D; Yang Z; Zhou K; Chen X; Sun R; Wang N; Liang Z; Bian S; Zhao J; Song P; Zheng S; Wang H; Xie H
    EBioMedicine; 2024 May; 103():105099. PubMed ID: 38604089
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. IFNα-induced BST2
    Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
    Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Novel acrylonitrile derived imidazo[4,5-b]pyridines as antioxidants and potent antiproliferative agents for pancreatic adenocarcinoma.
    Boček Pavlinac I; Persoons L; Daelemans D; Starčević K; Vianello R; Hranjec M
    Int J Biol Macromol; 2024 May; 266(Pt 2):131239. PubMed ID: 38569992
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
    Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
    World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Evidence of promoting effects of 6:2 Cl-PFESA on hepatocellular carcinoma proliferation in humans: An ideal alternative for PFOS in terms of environmental health?
    Hong J; Du K; Jin H; Chen Y; Jiang Y; Zhang W; Chen D; Zheng S; Cao L
    Environ Int; 2024 Apr; 186():108582. PubMed ID: 38513556
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
    Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
    Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Integrated clinical and prognostic analyses of mtor/Hippo pathway core genes in hepatocellular carcinoma.
    Feng T; Chen P; Wang T; Lai C; Yao Y
    J Physiol Biochem; 2024 May; 80(2):439-449. PubMed ID: 38468074
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. mtor inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.
    Zhang L; Liu P; Zhuang L; Ling S; Zhan Q; Zhou W; Su R; Yin L; Que Q; Hong J; Bao J; Shao C; Cai J; Zheng S; Xu X
    Mol Biomed; 2024 Mar; 5(1):9. PubMed ID: 38461206
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. XQZ3, a Chlorella pyrenoidosa polysaccharide suppresses cancer progression by restraining mitochondrial bioenergetics via HSP90/AKT signaling pathway.
    Sun L; Ji M; Liu Y; Zhang M; Zheng C; Wang P
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130705. PubMed ID: 38458300
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
    Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
    J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.
    Katsuya Y; Yoshida T; Takashima A; Yonemori K; Ohba A; Yazaki S; Yagishita S; Nakahama H; Kobayashi O; Yanagida M; Irino Y; Hamada A; Yamamoto N
    Int J Clin Oncol; 2024 Apr; 29(4):386-397. PubMed ID: 38381163
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinoma.
    Rampioni Vinciguerra GL; Capece M; Reggiani Bonetti L; Nigita G; Calore F; Rentsch S; Magistri P; Ballarin R; Di Benedetto F; Distefano R; Cirombella R; Vecchione A; Belletti B; Baldassarre G; Lovat F; Croce CM
    Signal Transduct Target Ther; 2024 Feb; 9(1):31. PubMed ID: 38342897
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mtor/NF-κB and MMP2/MMP9 signaling pathways in vitro.
    Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
    Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mtor pathway to promote the progression of pancreatic neuroendocrine neoplasms.
    Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
    J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Roles of Rictor alterations in gastrointestinal tumors (Review).
    Cao R; Guo S; Min L; Li P
    Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186315
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mtor-dependent pathway to drive hepatocellular carcinoma.
    Li X; Zhang CC; Lin XT; Zhang J; Zhang YJ; Yu HQ; Liu ZY; Gong Y; Zhang LD; Xie CM
    Exp Mol Med; 2024 Feb; 56(1):177-191. PubMed ID: 38177295
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 45.